TPM3 and neoplasm: NTRK inhibitors bind to Trk, thereby preventing ligand–Trk interaction and Trk activation, thus blocking the oncogenesis activity in cancer cells that overexpress NTRK fusion proteins, leading to both the induction of cellular apoptosis and the inhibition of cell growth in tumor cells.